Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M30,278Revenue $M580Net Margin (%)-127.3Z-Score11.9
Enterprise Value $M29,719EPS $-3.1Operating Margin %-119.4F-Score3
P/E(ttm))0Cash Flow Per Share $-0.3Pre-tax Margin (%)-126.7Higher ROA y-yN
Price/Book28.010-y EBITDA Growth Rate %0Quick Ratio4.1Cash flow > EarningsY
Price/Sales50.75-y EBITDA Growth Rate %0Current Ratio4.2Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-32.5Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-61.6Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M242ROI % (ttm)-31.5Gross Margin Increase y-yY

Gurus Latest Trades with VRTX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
VRTXVanguard Health Care Fund 2014-12-31 Reduce-0.58%$101.1 - $120.78
($112.61)
$ 125.0710%Reduce -16.93%9,808,860
VRTXKen Fisher 2014-09-30 Reduce$84.74 - $113.9
($94.97)
$ 125.0724%Reduce -31.99%4,593
VRTXVanguard Health Care Fund 2014-06-30 Add0.04%$62.44 - $94.68
($70.13)
$ 125.0744%Add 1.54%11,807,500
VRTXGeorge Soros 2014-06-30 Sold Out -0.01%$62.44 - $93.77
($69.73)
$ 125.0744%Sold Out0
VRTXKen Fisher 2014-06-30 Buy $62.44 - $93.77
($69.73)
$ 125.0744%New holding6,753
VRTXVanguard Health Care Fund 2014-03-31 Add0.13%$67.8 - $85.48
($79.08)
$ 125.0737%Add 5.89%11,628,500
VRTXGeorge Soros 2014-03-31 Buy 0.01%$67.8 - $85.48
($79.17)
$ 125.0737%New holding10,000
VRTXVanguard Health Care Fund 2013-12-31 Add0.88%$60.18 - $77.83
($69.45)
$ 125.0744%Add 54.06%10,981,500
VRTXVanguard Health Care Fund 2013-09-30 Add0.29%$74.53 - $88.51
($79.62)
$ 125.0736%Add 19.00%7,127,997
VRTXVanguard Health Care Fund 2013-06-30 Add1.05%$52.6 - $85.6
($73.64)
$ 125.0741%Add 140.58%5,990,000
VRTXNWQ Managers 2013-06-30 Sold Out -0.09%$52.6 - $85.6
($73.64)
$ 125.0741%Sold Out0
VRTXVanguard Health Care Fund 2013-03-31 Add0.05%$43.65 - $54.97
($48.01)
$ 125.0762%Add 10.97%2,489,800
VRTXNWQ Managers 2013-03-31 Reduce-0.02%$41.9 - $54.97
($47.91)
$ 125.0762%Reduce -23.44%191,032
VRTXGeorge Soros 2012-09-30 Sold Out -0.09%$48.38 - $59.07
($53.5)
$ 125.0757%Sold Out0
VRTXJoel Greenblatt 2012-09-30 Sold Out -0.08%$48.38 - $59.07
($53.5)
$ 125.0757%Sold Out0
VRTXNWQ Managers 2012-06-30 Reduce-0.27%$35.75 - $65.62
($50.92)
$ 125.0759%Reduce -83.86%188,842
VRTXVanguard Health Care Fund 2012-06-30 Reduce-0.08%$35.49 - $64.85
($51.21)
$ 125.0759%Reduce -15.13%2,243,700
VRTXJoel Greenblatt 2012-06-30 Buy 0.08%$35.75 - $65.62
($50.92)
$ 125.0759%New holding20,025
VRTXGeorge Soros 2012-06-30 Reduce-0.05%$35.75 - $65.62
($50.92)
$ 125.0759%Reduce -44.00%112,000
VRTXJean-Marie Eveillard 2012-06-30 Sold Out -0.02%$35.75 - $65.62
($50.92)
$ 125.0759%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

VRTX is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


VRTX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BOGER JOSHUA SDirector 2015-04-08Sell11,700$123.263.69view
MCGLYNN MARGARET GDirector 2015-04-06Sell12,500$118.367.98view
Chodakewitz JeffreyEVP GMDA, CMO 2015-04-02Sell2,291$115.510.66view
BOGER JOSHUA SDirector 2015-04-01Sell11,700$115.8710.3view
BOGER JOSHUA SDirector 2015-03-25Sell11,700$120.765.84view
Silva Paul MSVP & Corp Controller 2015-03-23Sell2,250$125.651.72view
SMITH IAN FEVP & CFO 2015-03-23Sell6,042$125.671.7view
Sachdev AmitEVP, Policy, Access & Value 2015-03-23Sell17,083$132.28-3.38view
SACHS BRUCE IDirector 2015-03-20Sell10,000$135.52-5.69view
Riley Wayne JosephDirector 2015-03-20Sell10,000$135.08-5.38view

Press Releases about VRTX :

Quarterly/Annual Reports about VRTX:

News about VRTX:

Articles On GuruFocus.com
J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
William Blair’s Top BioPharmaceutical Stock Picks for Q1 2015 Dec 23 2014 
Weekly CFO Sells Highlight: Texas Instruments Inc, Royal Caribbean Cruises Ltd, Vertex Pharmaceutica Nov 09 2014 
Weekly CFO Sells Highllight: Facebook Inc, Vertex Pharmaceuticals Inc, Nike Inc. Oct 06 2014 
Vanguard Health Care Fund Buys Vertex Pharmaceuticals, Zoetis Inc, , Sells Cerner Corporation, AbbVi Aug 02 2013 
Weekly Guru Bargains Highlights: MBI, VRTX, GRPN, PBI, PC Dec 16 2012 
WEEKLY CFO SELLS HIGHLIGHT: AKRX, FIO, OVRL, VRTX Oct 22 2012 
Idenix Pharmaceuticals Lagging Behind in Breakthrough Hepatitis C Drug Development Jul 13 2012 
Weekly Top Insider Sells: GMCR, VRTX, CERN, and AGN May 14 2012 
Vertex Could Climb On New Drug, VX-222 Success Apr 22 2012 

More From Our Partners
Stock Market News for April 09, 2015 - Market News Apr 9 2015 - ZACKS

More From Other Websites
Growth In Drug Spend Hits 13-Year High; Note To Pharma: Innovation Pays Apr 13 2015
Stocks Up For Second Week As GE Soars Apr 10 2015
Here are 10 local biotechs investing heavily in their future Apr 10 2015
The BBJ’s top real estate stories of the week: April 10, 2015 Apr 10 2015
Canaccord Ups Vertex To Buy On Cystic Fibrosis Drug Potential Apr 10 2015
Vertex to Announce First Quarter 2015 Financial Results on April 29 Apr 09 2015
Vertex to Announce First Quarter 2015 Financial Results on April 29 Apr 09 2015
Stock Market News for April 08, 2015 - Market News Apr 08 2015
Alnylam to move HQ to former Vertex site in big 2018 biotech shuffle Apr 06 2015
Is the FDA Worried About Vertex's New Drug? Mar 31 2015
Why Citigroup Removed Gilead Sciences From Its 'Most Preferred' List Mar 30 2015
11 promising drugs poised to be the next billion-dollar blockbusters Mar 27 2015
RBC Has 4 Biotech Stocks to Buy After Massive Pullback Mar 27 2015
The Zacks Analyst Blog Highlights: Biogen, Prothena, Vertex, Gilead and Amgen - Press Releases Mar 26 2015
One analyst is convinced the biotech stock plunge is 'misguided' Mar 26 2015
Vertex Falls on Disappointing Kalydeco+VX-661 Combo Data - Analyst Blog Mar 24 2015
Vertex Treatment May Have High Risk of Failure, Analyst Suggests Mar 24 2015
Stock Market News for March 24, 2015 - Market News Mar 24 2015
Deutsche Bank: Vertex Pharma's Disappointing VX-661 Trial Results Isn't The End Mar 23 2015
Vertex Falls Below Buy Point On Cystic-Fibrosis Drug Data Mar 23 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK